Changes of anti-citrullinated peptide antibodies titers after biologic treatment in patients with rheumatoid arthritis: a systematic literature review and retrospective study
Authors' conclusion
In this real-life study, ACPA titres only significantly decreased after treatment with rituximab.
Study context
- Population
- Rheumatoid arthritis (RA) patients treated with TNFi, abatacept or RTX with at least two anti-citrullinated peptide antibodies (ACPA) titres (one before and one after biologic treatment)
- Participants
- 59 / 31 / 55
- Exposure
- ACPA titres before vs after treatment with RTX, abatacept or TNFi
- Rituximabn = 59
- Abataceptn = 31
- TNFin = 55
- Outcome
- Change in ACPA titres after biologic treatment
Methodological detailsreal-life
- Real-life
Main finding
As reported in the abstract
ACPA titres before vs after treatment
- ACPA titres decreased significantly with rituximab but not with abatacept nor TNFi
- Modelling over follow-up confirmed significant decrease of ACPA over time with rituximab
Observational data: associations, not effects.
Further findings
Systematic literature review
- Articles retained
- 24
- Data on change in ACPA under biologics contradictory, particularly for abatacept and TNFi
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Changes of anti-citrullinated peptide antibodies titers after biologic treatment in patients with rheumatoid arthritis: a systematic literature review and retrospective study. Clin Exp Rheumatol. Published 23 June 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →